Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Ovarian Cancer Recurrent Clinical Trial

Official title:

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04175470
• Other study ID #: BeTo-Ovar
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 29, 2019
• Est. completion date: December 2024

Study information

• Verified date: May 2024
• Source: Vejle Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A recent study at the Department of Oncology, Vejle Hospital (NCT02399592), investigated bevacizumab and tocotrienol in ovarian cancer patients and concurrently monitored the level of methylated HOXA9 circulating tumor DNA (HOXA9 meth-ctDNA) in the blood.

The rate of disease control was 70% with better results than other studies using bevacizumab alone. The toxicity was very low and attributed to bevacizumab only.

When the study results were worked up they showed that patients with a significant increase of HOXA9 meth-ctDNA after the first cycle of treatment did not benefit from the treatment whereas those with stable or decreasing HOXA9 meth-ctDNA did.

Therefore, in the current study patients with a high increase of HOXA9 meth-ctDNA after the first treatment cycle will discontinue treatment, as it is then considered ineffective. The remaining patients may achieve prolonged survival as predicted by their level of HOXA9 meth-ctDNA.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed epithelial ovarian cancer, primary fallopian or primary peritoneal cancer.

• Platinum resistant epithelial ovarian cancer treated with at least two different previous chemotherapeutic regimens

• Progression on previous treatment. Previous treatment with bevacizumab is allowed.

• Measurable disease by the RECIST 1.1 criteria or evaluable by the GCIG CA-125 criteria.

• Age = 18 years.

• Performance status 0-2.

• Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):

• WBC = 3.0 x 10^9/l or neutrophils (ANC) = 1.5 x 10^9/l

• Platelet count = 100 x 10^9/l

• Hemoglobin = 6 mmol/l

• Serum bilirubin < 2.0 x ULN

• Serum transaminase = 2.5 x ULN

• Serum creatinine = 1.5 ULN

• Urine dipstick for protein < 2+. If the dipstick shows protein = 2+, 24 hour urine testing must be performed and show protein contents < 1 g.

• Written informed consent

Exclusion Criteria:

• Other malignant disease within 3 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin.

• Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.

• Intestinal infiltration or infiltration in major blood vessels at the discretion of the treating physician.

• Underlying medical disease not adequately treated (diabetes, cardiac disease).

• Uncontrolled hypertension (BP > 150/100 despite antihypertensive treatment).

• Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab.

• Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within 6 months before start of treatment.

• Clinical significant cardiovascular disease, including:

• Myocardial infarction or unstable angina within 6 months before start of treatment

• New York Heart Association (NYHA) class = 2

• Poorly controlled cardiac arrhythmia despite medication

• Peripheral vascular disease grade = 3

• Allergy to active substance or any of the auxiliary agents

• Bleeding tumor

• Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.

• Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer Recurrent
• Ovarian Neoplasms
• Recurrence

Intervention

Drug:
• Bevacizumab
10 mg/kg intravenously every three weeks

Dietary Supplement:
• Tocotrienol
Capsules, 300 mg orally three times daily

Locations

Country	Name	City	State
Denmark	Department of Oncology, Vejle Hospital	Vejle

Sponsors (1)

Lead Sponsor	Collaborator
Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival		6 months after enrollment of the last patient
Secondary	Overall survival		12 months after enrollment of the last patient
Secondary	Response rate as measured by RECIST 1.1 or CA-125		6 months after enrollment of the last patient
Secondary	Safety as measured by CTC version 5.0	CTC = National Cancer Institute's Common Toxicity Criteria (NCI-CTC)	Every 9 weeks until progression, up to 3 years